Kornimate/medical-research-clean huggingface dataset:
prevalence and prognostic effects of thyroid abnormalities in patients with acute coronary syndrome.

Conditions: Thyroid Dysfunction

Summary: the goal of this observational study is knowledge of prevalence of throid abnormalities in patients with acute coronary syndrome and prognostic effects of thyroid abnormalities in patients with acute coronary syndrome as early detection and management of thyroid abnormalities can improve clinical outcomes.

acute coronary syndrome (acs) is an umbrella term used to describe a range of conditions associated with sudden, reduced blood flow to the heart. acs includes conditions such as: unstable angina, non-st-elevation myocardial infarction (nstemi) and st-elevation myocardial infarction (stemi). the morbidity and mortality due to acs are substantial-nearly half of all deaths due to coronary heart disease occur following an acs . thyroid abnormalities, particularly hypothyroidism and hyperthyroidism, are relatively common in patients with acs. studies indicate that thyroid dysfunction can affect cardiovascular health, influencing the risk and prognosis of acs. reports suggest prevalence rates of hypothyroidism 10-20% and hyperthyroidism range from 1-5% in acs patients . hypothyroidism is associated with elevated cholesterol levels, increased vascular stiffness, and heightened inflammation, can lead to reduced cardiac output and heart rate and increased incidence of heart failure and arrhythmias. all of which can exacerbate coronary artery disease and contributing to worse outcomes during acs event. hypothyroid patients often have a slower recovery and poorer response to standard acs treatments, including thrombolytics and antiplatelet therapy. hyperthyroidism raises heart rate and contractility, leading to increased myocardial oxygen demand, which can worsen ischemia during acs, patients are more susceptible to arrhythmias, which can complicate acs and lead to higher morbidity and mortality, hyperthyroidism can cause vascular endothelial dysfunction, increasing the risk of thrombotic events during acs and patients may respond differently to standard acs therapies, necessitating careful monitoring and potential adjustment of treatment strategies. patients with concurrent thyroid dysfunction often experience higher morbidity and mortality rates, so thyroid function should be routinely assessed in acs patients, as early detection and management of thyroid abnormalities can improve clinical outcomes.

Eligibility criteria:
inclusion criteria: * patients with acs: (stemi_nstemi) exclusion criteria: * 1-patients with cardiogenic shock. 2- patients with other endocrinal diseases. 3- patients on dialysis. 4-patients with acute malignancy. 5-patient with thyroid diseases on treatment. 6- patients with liver diseases. 7-patients with any autoimmune diseases
clinical biomarker of paclitaxel-induced peripheral neuropathy

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: investigation of which patients treated with paclitaxel have an increased risk of developing peripheral neuropathy.

the primary aim of this study is to validate the protein neurofilament light chain (nfl) as a biomarker of the side effect paclitaxel-induced peripheral neuropathy (pipn) and its utility in predicting this side effect in patients with breast cancer. the investigators want to include 188 patients at four different trial sites. the patients must follow their normal treatment cycles while getting blood drawn during their treatment period however maximal 4 cycles. blood samples are dawn before treatment initiation and once before each new cycle start in order to measure neurofilament light chain (nfl) before and during treatment. the investigators also want to take a skin biopsy before treatment start and after either cycle 3 or 4. the primary endpoint of the study is if serum nfl\>100 pg/ml after first cycle of paclitaxel can predict early termination of paclitaxel due to peripheral neuropathy.

Eligibility criteria:
inclusion criteria: * age \> 18 years * willing to give informed consent * scheduled to receive neo-adjuvant or adjuvant paclitaxel treatment * able to speak and understand danish * diagnosed with breast cancer * paclitaxel naïve patients exclusion criteria: * neurodegenerative diseases (e.g., neuropathy from another cause, previous apoplexy, disc herniation * type 1 or 2 diabetes * pregnant * breastfeeding * relapse of cancer diagnosis * diagnosed with human immunodeficiency virus (hiv) * participation in other clinical trials where the dose of paclitaxel is changed, or the aim is to prevent neuropathic pain or decrease nfl level (except if the intervention is to use cooling gloves). * previous treatment with neurotoxic chemotherapy * chronic pain from another cause * metastatic cancer
internet-cbt (cognitive behavioral therapy) for depression and anxiety in parkinsons disease

Conditions: Parkinson's Disease; Depression; Anxiety; Insomnia

Summary: the purpose of this project is to develop and evaluate internet-based cognitive behavioral therapy (icbt) for parkinson's disease (pd) patients with concurrent depression or anxiety symptoms. all treatment in this project is given as an adjunct to standard medical treatment (smt). icbt will be compared to an internet-based active control treatment (icontrol) and to smt alone. it is hypothesized that both active treatments will be superior to smt, and that icbt will be superior to icontrol, in reducing symptoms of depression and anxiety.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease * at least mild to moderate depression or anxiety defined as hads-a or hads-d \> 7 exclusion criteria: * has a high alcohol or drug use assessed by the audit / dudit and assessment interview * somatic or psychiatric problems that are directly contraindicated or seriously hamper the implementation of the treatment (eg, psychotic disorders or bipolar disorder) * difficulties that hamper the use of a computer * the patient states difficulties in finding enough time for treatment * too low cognitive functioning defined as moca \< 24 * too severe depression, defined as madrs-s over 30 * too high suicidal risk defined as more than 4 points on the madrs-s question 9 or according to the structured assessment interview

Keywords: self-help treatment internet treatment cognitive behavioral therapy internet-based cognitive behavioral therapy
fmri in posttraumatic stress disorder (ptsd) during working memory updating

Conditions: Post-Traumatic Stress Disorders; Anxiety; Amnesia, Dissociative

Summary: neuropsychological studies investigating trauma-exposed and posttraumatic stress disorder (ptsd) subjects have generally underlined the significantly poorer performance of tasks that require attention, concentration, and verbal memory, and difficulty in regulating memories surrounding the traumatic event. a previous study (el hage et al. cognitive neuropsychiatry, 2006) revealed that the trauma-exposed subjects scored higher on anxiety/depression scales, and lower on processing speed tests. moreover, the study showed significant impairment in working memory partially mediated by speed processing, but not by anxiety or depression. these results suggest that processing speed makes a major contribution to trauma-related working memory decline, and needs to be investigated in further studies.the aim of the present study is to explore correlation between hippocampus volume, frontal dysfunction and cognitive slowing in trauma-exposed subjects, while examining brain activation during performance of working memory tasks using functional magnetic resonance.

working memory performance will be assessed using the "3-back test", and processing speed evaluated with "words comparison test". the study will be conducted on 2 years. the study should include 18 right-handed females victims of sexual abuse and suffering from ptsd, and 18 controls right-handed females without any history of abuse ad not suffering from ptsd. brain activation will be measured during performance of working memory tasks (3-back test) and processing speed test using functional magnetic resonance.

Eligibility criteria:
inclusion criteria: * right-handed women * victim of sexual abuse * suffering from ptsd exclusion criteria: * epilepsy * claustrophobia * mri contre-indication * addictive disorders * sightless * detection of a brain injury at the mri

Keywords: ptsd mri, functional anxiety working memory processing speed
study to assess fixed dosing of amg 223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia

Conditions: End Stage Renal Disease; Chronic Kidney Disease; Hyperphosphatemic; Kidney Disease

Summary: the primary objectives of this study are the following: 1. to demonstrate that amg 223 will produce a statistically significant reduction in serum phosphorus compared with placebo over a 3 week treatment period in subjects with ckd receiving dialysis 2. to describe a dose response for amg 223 3. to evaluate the safety and tolerability of amg 223


Eligibility criteria:
inclusion criteria: * maintenance hemodialysis 3 times a week for at least 3 months prior to screening * single pool kt/v at least 1.2 or urea reduction ratio at least 65% * serum phosphorus level of 3.5 to 6.5 mg/dl inclusive at screening * no change(s) in type or dose of non-investigational phosphate binder(s) for at least 1 month prior to screening * serum albumin \> 3.0 mg/dl at screening * if applicable, an increase in serum phosphorus of greater than or equal to 1.5 mg/dl, and a serum phophorous level \> 5.5 mg/dl and less than or equal to 10 mg/dl during the washout period * if applicable, stable doses (defined as no change in dose for at least 1 month prior to screening) of vitamin d replacement, calcimimetic agents, or bedtime calcium supplements * willingness to avoid intentional changes in diet such as fasting or dieting exclusion criteria: * previous intolerance leading to discontinuation of polymer-based phosphate binder therapy * history of noncompliance with phosphate binder therapy in the opinion of the investigator * anticipating or scheduled for a living related-donor kidney transplant, or a prior recipient of a kidney transplant * current use of antiarrhythmic or anti-seizure medication * active ethanol or drug dependence or abuse, excluding tobacco use * a screening serum calcium (corrected for albumin) \< 8.4 mg/dl * history of bowel obstruction, swallowing disorders, severe gastrointestinal disorders, major gastrointestinal surgery, or gastric/duodenal ulcers within 6 months prior to screening * subject is pregnant, breast feeding, or is of child bearing potential and is not using adequate contraceptive precautions * subject is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s) * subject has experienced a myocardial infarction or major surgery (excluding vascular access surgery) within 3 months prior to screening * clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of localized basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia
adherence and quality of life in people with schizophrenia and schizoaffective disorder

Conditions: Schizophrenia; Schizoaffective Disorder; Quality of Life

Summary: it is the goal of this study adherence and quality of life in a population of people suffering from schizophrenia or schizoaffective disorder and to analyze if these factors are influenced by treatment, support, social services, and residential treatment. the study population is drawn from the the cantons glarus and graubunden as well as liechtenstein.


Eligibility criteria:
inclusion criteria: * schizophrenia or schizoaffective disorder * 18 - 65 years old * treated in the pdgr within the past 19 years exclusion criteria: * organic brain disorder * alcohol or drug dependence * low intelligence * unable to give consent * no legal competency * lacking knowledge of german language * current psychiatric inpatient treatment

Keywords: adherence
patient preference comparison of azarga versus cosopt

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study was to assess patient preference regarding ocular comfort of azarga® compared to cosopt® after one week instillation of each study medication.

at the screening visit, each intervention was instilled in one eye in a contralateral fashion to establish baseline ocular comfort prior to randomization. a 48-hour washout period separated the two treatment periods.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ocular hypertension, open-angle with or without pseudoexfoliation or pigment dispersion glaucoma in both eyes. * on a stable regimen of intraocular pressure-lowering (iop) medication within 30 days of screening visit. * iop considered safe (in the opinion of the investigator) in both eyes in such a way that assures clinical stability of vision and the optic nerve throughout the study period. * iop between 19 and 35 millimeters mercury (mmhg) in at least one eye (study eye). * willing to discontinue the use of all other ocular drugs (prescribed and over-the-counter) prior to receiving the screening dose during the screening visit and for the entire course of the study. * able to follow instructions and willing and able to attend all study visits. * read, sign, and date an ethics committee reviewed and approved informed consent form. * other protocol-defined inclusion criteria may apply. exclusion criteria: * known medical history of allergy, hypersensitivity or poor tolerance to any component of the preparations to be used in this study that is deemed clinically significant in the opinion of the principal investigator. * best corrected visual acuity worse than 20/80 snellen in either eye. * any abnormality preventing reliable applanation tonometry in either eye. * intraocular conventional surgery or laser surgery in either eye less than 3 months prior to the screening visit. * risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment. * progressive retinal or optic nerve disease from any cause. * history of ocular herpes simplex. * severe allergic rhinitis or bronchial hypersensitivity that would preclude the safe administration of a topical beta-blocker. * bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker. * women who are pregnant, lactating, or of childbearing potential and not using a reliable means of birth control. * participation in any other investigational study within 30 days prior to the screening/baseline visit. * other protocol-defined exclusion criteria may apply.

Keywords: glaucoma intraocular pressure tonometry, ocular
evaluation of chronic hbv patients w/evidence of hbv replication and normal or minimally elevated liver transaminases.

Conditions: Chronic Hepatitis B

Summary: to determine whether hbeag-positive and hbeag-negative patients with hbv dna greater than or less than 5 log10 and 4 log10 copies/ml, respectively, and with normal or minimally elevated liver transaminases have histological evidence of active liver disease.

to determine whether hbeag-positive and hbeag-negative patients with hbv dna greater than or less than 5 log10 and 4 log10 copies/ml, respectively, and with normal or minimally elevated liver transaminases have histological evidence of active liver disease.

Eligibility criteria:
inclusion criteria: patients must meet all of the following inclusion criteria to be included in this study: age greater than or equal to 18 years. documented laboratory diagnosis of hbv infection (hbsag positive) at least 6 months prior to inclusion in this study. treatment naive, hbeag-positive and hbeag-negative patients. at least one liver biopsy specimen obtained in 2004 and/or 2005 (post diagnosis) that is available for evaluation by an independent pathologist. gilead may allow enrollment of subjects with biopsies available from 2003. an adequate section of a biopsy for the purposes of this study should have at least 1 cm of the needle core of tissue on the slide. hbv dna greater than or less than 5 log10 copies/ml for hbeag-positive and greater than or less than 4 log10 copies/ml for hbeag negative patients. a minimum of two normal or minimally elevated hepatic transminases (alt) values that are at least 3 months apart during 2004 and/or 2005. gilead may allow enrollment of subjects with values available from 2003. minimally elevated alt is defined as between lower limit of normal (lln) and 1.2 times upper limit of normal (uln) for hbeag-positive and between lower limit of normal (lln) and 1.5 times upper limit of normal (uln) for hbeag-negative patients. child-turcotte-pugh score less than 7 and no evidence of ascites, variceal bleeding, or hepatic encephalopathy or impaired clotting function within 12 months prior to the enrollment visit. exclusion criteria:patients who meet any of the following criteria are excluded from the study: history or evidence of hiv, hepatitic c, or hepatitis d. other causes for liver disease other than hepatitis b, including but not limited to: hemochromatosis, alpha-1 antitrypsin deficiency, wilson's disease, drug-related liver disease, autoimmune hepatitis, alcoholic liver disease, obesity-induced liver disease (nonalcoholic seatohepatitis, nash). history of, or current alcohol or substance abuse judged by the investigator to potentially interfere with laboratory or biopsy results.
psychological impact in diabetes: intervention with affect school and basal body awareness

Conditions: Diabetes Mellitus; Depression; Alexithymia; Anxiety

Summary: psychological impact, metabolic control, and biological stress markers in diabetes: intervention study with affect school and basal body awareness background: depression is common in patients with diabetes and is associated with impaired metabolic control. alexithymia has been associated with depression, anxiety, stress related disorders and diabetes mellitus. affect school (as) is an intervention that may reduce depression and alexithymia according to previous research. basic body awareness therapy (bba) is a stress-reducing technique. purpose: our aim is to: 1. analyze the prevalence of depression and anxiety and the personality variables alexithymia and self image in diabetes patients. 2. explore correlations between these variables and risk factors, including biochemical markers for diabetic complications. 3. to evaluate an intervention with as and bba in patients with diabetes that scored high in psychometric self-report tests and at the same time showed impaired metabolic control. method: a randomized controlled trial of 350 people with diabetes, 18-59 years, 56% men, 44% women. base-line study: from medical records and the national diabetes registry - waist circumference, bmi, blood pressure, type and duration of diabetes, diabetes complications, other diseases, medications, exercise habits and smoking. tests - a1c, blood lipids, cytokines, hormones, beta-cell antibodies, c-peptide, midnight cortisol (salivary). self-report tests of psychological and personality variables: had, tas-20, sasb. intervention: patients with a1c ≥ 8 and anxiety (had ≥ 8), depression (had ≥ 8), negative self-image (sasb: aff \<284) or alexithymia (tas-20 ≥ 61) were randomized to as or bba. as: 8 group sessions followed by 10 individual sessions. instructors were a primary care physician and a psychotherapist. bba: 9 group meetings and 6 individual sessions with a physiotherapist as instructor. post intervention: self report tests, a1c, cytokines, hormones, cortisol.


Eligibility criteria:
inclusion criteria: * type 1 and type 2 diabetes at a specialist outpatient clinic in vaxjo exclusion criteria: * other severe somatic disorder, including being deaf or blind. * severe psychiatric disorder requiring psychiatric specialist care; * psychotic disorder, * bipolar disorder, * severe drug abuse. * inadequate knowledge of swedish.

Keywords: diabetes mellitus depression anxiety negative self image alexithymia metabolic control diabetes complications
eyelid movement sensor device- blinking characterizing

Conditions: Eyelid Movement Disorders

Summary: the investigators have developed a simple to use device that facilitates the monitoring of the upper eyelids motion, acquires the eyelid vertical movement and enables analysis and graphic presentation of the results. the device system consists 3 components : glasses for the patient including magneto sensitive probes, hardware and dedicated software. our purpose is to characterize eyelid motion in normal population. the methods include measuring each patient 10 minutes during watching a short movie.

essentially, for hall-probes monitor the magnetic field generated by a tiny magnets attached to the upper eyelid.

Eligibility criteria:
inclusion criteria: * healthy 18-67 year olds with no eye medical history exclusion criteria: * pregnancy * head trauma history * using contact lens
lactobacillus reuteri in the prevention of antibiotic associated-diarrhea and clostridium difficile

Conditions: Antibiotic-associated Diarrhea; Clostridium Difficile

Summary: the purpose of this study is to find whether lactobacillus reuteri prevents antibiotic-associated diarrhea and related clostridium difficile infections. subjects will be admitted from the university hospitals case medical center. they will be randomly assigned to an intervention group receiving l. reuteri or a placebo. supplementation will occur during antibiotic treatment and for an additional 7 days after cessation of treatment. data collection will occur at baseline, end of antibiotic use, 7 days after antibiotic cessation, and 21 days after antibiotic cessation. primary data includes diarrhea instances. secondary data includes severity of diarrhea, presence of c. difficile toxins, and presence of other gi symptoms.

the data being measured for this study include: primary outcome = incidence of diarrhea during and after treatment with antibiotics. an episode of diarrhea is defined as the discrete period between the time when stool output meets or exceeds three soft and unformed or watery bowel movements to the time when formed stools return, which must be at least 48 hours later. secondary variables: 1. severity of diarrhea measured as the discrete period between the time when stool output meets or exceeds 3 soft and unformed or watery bowel movements to the time when formed stools return. 2. frequency of stool samples positive for c. difficile toxin a or b at baseline, when presenting with diarrhea during the study period, and at the follow-up 21 days post-antibiotic-treatment to detect possible clearance of c. difficile, in patients ingesting l. reuteri versus placebo. 3. frequencies of other gastrointestinal symptoms at 1, 2, and 4 weeks, in the l. reuteri group versus placebo and assessed by the validated gastrointestinal symptom rating score.

Eligibility criteria:
inclusion criteria: * receiving antibiotics for not more than 48 hours prior to enrollment and free from diarrhea * able to understand and sign informed consent and hippa * available throughout the study period * subjects should have the mental ability to understand and willingness to fulfill all the details of the protocol exclusion criteria: * three or more soft and unformed or watery stools per day at admission * receiving chemotherapy or radiation therapy * diagnosis of inflammatory bowel disease * npo without po meds * neutropenia (an absolute neutrophil count (anc) of less than 1500/microl) * hiv positive with a cd4+ t-lymphocyte count \<400 per mcl blood * requiring care in an intensive care unit * status-post bowel resection during hospitalization * patient's receiving antibiotics four weeks prior to hospitalization * patient with severe life threatening illness or immunocompromised * pregnancy

Keywords: induced diarrhea clostridium difficile toxicity